Newsoara Biopharma Co., Ltd.
Clinical trials sponsored by Newsoara Biopharma Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug HY8931 put to the test in healthy volunteers Results expected Sep 2026 (estimated)
- New drug HY6725 enters first human safety tests Results expected Mar 2027 (estimated)
-
New oral pill HPP737 takes on psoriasis in Head-to-Head trial
Disease control CompletedThis Phase 3 trial tests whether an experimental oral drug, HPP737, can reduce psoriasis severity in adults with moderate-to-severe plaque psoriasis. Participants take HPP737 or an active control drug daily for 16 weeks. Researchers measure skin clearance using standard scores li…
Phase 3 • Sponsor: Newsoara Biopharma Co., Ltd. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New oral pill HPP737 aims to clear psoriasis in phase 3 trial
Disease control CompletedThis Phase 3 trial tests whether an oral drug called HPP737 can safely improve moderate-to-severe plaque psoriasis in adults. Participants take HPP737 or a placebo daily for 16 weeks, with doctors measuring skin clearance using standard scores like PASI. The study aims to see if …
Phase 3 • Sponsor: Newsoara Biopharma Co., Ltd. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New oral pill HPP737 aims to clear psoriasis in phase II trial
Disease control CompletedThis trial tests whether an oral drug called HPP737 can safely improve moderate-to-severe plaque psoriasis in adults. Participants take either HPP737 or a placebo daily for 85 days. Researchers measure skin improvement using standard scoring tools and track any side effects. The …
Phase 2 • Sponsor: Newsoara Biopharma Co., Ltd. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC